Antitumor activity of aumolertinib, a third-generation EGFR tyrosine kinase inhibitor, in non-small-cell lung cancer harboring uncommon EGFR mutations

• Main Authors: Chen Shi (Author), Cong Zhang (Author), Zhiwen Fu (Author), Jinmei Liu (Author), Yuanfeng Zhou (Author), Bao Cheng (Author), Cong Wang (Author), Shijun Li (Author), Yu Zhang (Author)
• Format: Book
• Published: Elsevier, 2023-06-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Uncommon epidermal growth factor receptor (EGFR) mutations account for 10%-20% of all EGFR mutations in non-small-cell lung cancer (NSCLC). The uncommon EGFR-mutated NSCLC is associated with poor clinical outcomes and generally achieved unsatisfactory effects to the current therapies using standard...